GT Biopharma Inc
GTBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.51M
Close$
$1.24
252.6% upside
Current Fair Value
252.6% upsideUndervalued by 252.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.51 Million |
|---|---|
| Enterprise Value | $-4,408,715.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.25 |
| Beta | 0.84 |
| Outstanding Shares | 30,283,031 |
Return
| Return on Equity | -408.27% |
|---|---|
| Return on Assets | -309.59% |
| Return on Invested Capital | -481.19% |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | -0.02 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.12 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.55%▼ 28.71% |
|---|---|
| Total Invested | $81,634▼ 87.57% |
| Investors Holding | 6▼ 33.00% |
ESG Score
No data
About GT Biopharma Inc
2,018 employees
CEO: Anthony Cataldo GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is desig...